Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : BB Biotech: Gains realized -2-

10/22/2021 | 05:17am EST

Disclaimer This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors. Composition of BB Biotech's portfolio as at September 30, 2021 (in % of securities, rounded values)

Moderna                                    14.7% 
Ionis Pharmaceuticals                       7.0% 
Argenx SE                                   6.6% 
Neurocrine Biosciences                      6.4% 
Alnylam Pharmaceuticals                     4.8% 
Incyte                                      4.5% 
Agios Pharmaceuticals                       4.5% 
Vertex Pharmaceuticals                      4.3% 
Fate Therapeutics                           4.3% 
Arvinas                                     4.1% 
Macrogenics                                 3.4% 
Biogen                                      3.2% 
Sage Therapeutics                           3.2% 
Intra-Cellular Therapies                    3.1% 
Myovant Sciences                            2.9% 
Relay Therapeutics                          2.7% 
Crispr Therapeutics                         2.4% 
Radius Health                               2.2% 
Revolution Medicines                        2.1% 
Scholar Rock Holding                        1.7% 
Molecular Templates                         1.6% 
Generation Bio Co.                          1.4% 
Exelixis                                    1.4% 
Esperion Therapeutics                       1.2% 
Beam Therapeutics                           1.2% 
Nektar Therapeutics                         1.1% 
Essa Pharma                                 0.9% 
Kezar Life Sciences                         0.9% 
Mersana Therapeutics                        0.9% 
Black Diamond Therapeutics                  0.7% 
Homology Medicines                          0.3% 
Wave Life Sciences                          0.3% 
Alder Biopharmaceuticals - CVR              0.1% 
Total securities                  CHF 4 093.1 mn 
Other assets                          CHF 1.9 mn 
Other liabilities                 CHF (261.8) mn 
Net Asset Value                   CHF 3 833.2 mn 


2021-10-22 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1242645 
End of News   DGAP News Service 

1242645 2021-10-22

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1242645&application_name=news

(END) Dow Jones Newswires

October 22, 2021 05:16 ET (09:16 GMT)

All news about BB BIOTECH AG
10/22BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
10/22BB BIOTECH : Q3 Net Loss Shrinks
10/22BB BIOTECH : increases positions in oncology and CNS
10/22BB BIOTECH : publishes its interim report
10/22BB BIOTECH : Gains realized following COVID-19 vaccine booster update enable increases in ..
07/23Bb Biotech Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
07/23BB BIOTECH : Posts Lower H1 Profit, Operating Income
07/23BB BIOTECH : Interim report as at June 30, 2021
07/23BB BIOTECH : publishes its interim report
07/23BB BIOTECH : Solid second quarter for the biotech industry - BB Biotech raised its allocat..
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Sales 2021 -175 M -190 M -190 M
Net income 2021 439 M 476 M 476 M
Net Debt 2021 23,5 M 25,4 M 25,4 M
P/E ratio 2021 7,67x
Yield 2021 5,15%
Capitalization 4 321 M 4 682 M 4 681 M
EV / Sales 2021 -24,8x
EV / Sales 2022 -
Nbr of Employees 10
Free-Float 98,1%
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 78,00 CHF
Average target price 97,00 CHF
Spread / Average Target 24,4%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG5.19%4 682
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431